Fennec logo.jpg
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
March 17, 2024 21:00 ET | Fennec Pharmaceuticals Inc.
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of...
Eloxx.jpg
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
March 13, 2024 11:42 ET | Eloxx Pharmaceuticals
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready...
allogene.png
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
March 12, 2024 08:30 ET | Allogene Therapeutics, Inc.
Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025...
PMB Aerospace Corporation Announces Exclusive License of Battery Technology
March 11, 2024 08:00 ET | PMB Aerospace Corporation
PMB AEROSPACE CORPORATION ANNOUNCES EXCLUSIVE LICENSE OF BATTERY TECHNOLOGY
Nurix.png
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
March 11, 2024 07:00 ET | Nurix Therapeutics, Inc.
Nurix's Phase 1a/1b study of NX-2127 in adults with r/r B-cell malignancies to enroll new patients after partial clinical hold lifted
Lifeist.png
Aussie Vapes Granted Import License in Australia  
March 08, 2024 07:00 ET | Lifeist Wellness Inc.
TORONTO, March 08, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in...
solid-1029x579.png
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
March 07, 2024 07:00 ET | Solid Biosciences Inc.
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
CPS Logo 090121.png
CPS Technologies and Triton Systems Announce New Licensing Agreement
March 06, 2024 08:00 ET | CPS Technologies Corp.
NORTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) (“CPS”) and Triton Systems, Inc. (“Triton”) today announced they have signed a manufacturing licensing...
Kraig Biocraft Laboratories Preparing Additional Business Investment License to Advance its Business Operations
March 06, 2024 07:05 ET | Kraig Biocraft Laboratories
Kraig Labs (OTCQB:KBLB) expects to submit its second business investment application in Vietnam as part of the planned expansion of its business operations
C4Therapeutics-Website-Logo-FullColor-(R).png
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
March 04, 2024 07:00 ET | C4 Therapeutics, Inc.
Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery...